〔Abstract〕 Objective To observe the clinical efficacy of Guanxinning tablets combined with sakobactri valsartan in the treatment of coronary heart disease complicated with chronic heart failure (CHF), and to provide scientific basis for clinical medical practice. Methods A total of 100 patients with coronary heart disease complicated with CHF admitted to Shenzhen Traditional Chinese Medicine Hospital from February 2019 to October 2021 were randomly divided into an observation group and a control group, with 50 cases in each group. The control group was treated with sakobactri valsartan on the basis of conventional treatment, and the observation group was treated with guanxining tablets on the basis of the control group, for a course of 6 months. Clinical efficacy of the two groups were observed and compared. CHF markers: N terminal pro B type natriuretic peptide (NT-proBNP) and brain natriuretic peptide (BNP); cardiac function indicators: left ventricular ejection fraction (LVEF), left ventricular end diastolic diameter (LVEDD) and left ventricular end systolic diameter (LVESD), 6 min walking test (6MWT); neuroendocrine hormone: angiotensin Ⅱ (AngⅡ), aldosterone (ALD) and plasma renin activity (PRA); blood lipid levels: triglyceride (TG), total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C); adverse reactions during treatment were recorded. Results The total effective rate of the observation group was 94.0%, higher than 78.0% of the control group, the difference was statistically significant (P < 0.05). After treatment, the serum NT-proBNP and BNP of the two groups of patients were lower than those before treatment, the serum NT-proBNP and BNP of the observation group were lower than those of the control group, the differences were statistically significant (P < 0.05). After treatment, LVEF in the two groups was increased, LVEDD and LVESD were decreased, and LVEF in the observation group was higher than that of the control group, while LVEDD and LVESD were lower than those of the control group, the differences were statistically significant (P < 0.05). After treatment, 6MWT in the two groups was higher than that before treatment, and 6MWT in the observation group was longer than that in the control group, the difference was statistically significant (P < 0.05). After treatment, AngⅡ, ALD and PRA in the two groups were lower than before treatment, and AngⅡ, ALD and PRA in the observation group were lower than those of the control group, the differences were statistically significant (P < 0.05). After treatment, TG, TC and LDL-C in the two groups were lower than those before treatment, while HDL-C was higher than that before treatment, TG, TC and LDL-C in the observation group were lower than those of the control group, while HDL-C was higher than that of the control group, the differences were statistically significant (P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P > 0.05). ConclusionGuanxinning tablets combined with sakubattrel valsartan can improve the clinical efficacy of coronary heart disease complicated with CHF, improve cardiac function and blood lipid level, regulate neuroendocrine hormone, and has good safety